ORF Biologics, Inc.
ORF Biologics, Inc. is a biotechnology company based in Tiffin, Iowa, specializing in the design, development, and manufacturing of advanced biologics for research and therapeutic applications. With over 45 years of industry experience, the company pioneers next-generation biologics, focusing on custom and off-the-shelf solutions for pharmaceutical and biotech companies. ORF Biologics is committed to accelerating scientific discovery through innovative protein engineering, synthetic biology, and rigorous quality control, serving critical fields such as infectious disease, neurodegeneration, regenerative medicine, and biosecurity.
Industries
N/A
Nr. of Employees
small (1-50)
ORF Biologics, Inc.
Products
Recombinant Human Activin A
Lyophilized recombinant human Activin A supplied for research use; provided with purity and bioactivity specifications for use in stem cell differentiation and developmental biology applications.
CHO-K1 and HEK293 cell lines and matched growth media
Standard mammalian cell lines offered with optimized growth media formulations tailored for performance in research and protein production workflows.
Recombinant Human Activin A
Lyophilized recombinant human Activin A supplied for research use; provided with purity and bioactivity specifications for use in stem cell differentiation and developmental biology applications.
CHO-K1 and HEK293 cell lines and matched growth media
Standard mammalian cell lines offered with optimized growth media formulations tailored for performance in research and protein production workflows.
Services
End-to-end development of custom recombinant biologics including design, expression, purification, validation, and delivery for research and preclinical applications.
Commercial availability of recombinant proteins, growth factors, cell lines, and media for immediate purchase and use in research workflows.
Collaborative development of regulatory-aligned assays and bioanalytical methods, leveraging partnerships with GLP-capable CROs to support validation and preclinical testing.
End-to-end development of custom recombinant biologics including design, expression, purification, validation, and delivery for research and preclinical applications.
Commercial availability of recombinant proteins, growth factors, cell lines, and media for immediate purchase and use in research workflows.
Collaborative development of regulatory-aligned assays and bioanalytical methods, leveraging partnerships with GLP-capable CROs to support validation and preclinical testing.
Expertise Areas
- Recombinant protein expression
- Synthetic biology and protein engineering
- Assay development and bioanalytics
- Cell line provision and media development
Key Technologies
- Recombinant protein expression systems
- Plasmid production and genetic engineering
- Downstream protein purification
- Lyophilization and cold-chain handling
News & Updates
Open house event on July 18, 2025, offering tours of lab facilities, team meet-and-greet, and insights into the company's mission and work.
Participation in Bio 2025 in Boston from June 16-19, 2025, showcasing advancements in biologics at Exhibitor Booth 1789.
Announcement of a strategic partnership with Vipragen Biosciences Pvt. Ltd. to accelerate innovation in drug discovery research and assay development, combining expertise in recombinant protein technologies and preclinical research.
Launch of standard CHO-K1 and HEK293 cell lines with custom-matched growth media for research and production environments.
Announcement of innovative approaches to the design and manufacturing of standard and custom biologics, including peptides, proteins, and antibodies.
Open house event on July 18, 2025, offering tours of lab facilities, team meet-and-greet, and insights into the company's mission and work.
Participation in Bio 2025 in Boston from June 16-19, 2025, showcasing advancements in biologics at Exhibitor Booth 1789.
Announcement of a strategic partnership with Vipragen Biosciences Pvt. Ltd. to accelerate innovation in drug discovery research and assay development, combining expertise in recombinant protein technologies and preclinical research.
Launch of standard CHO-K1 and HEK293 cell lines with custom-matched growth media for research and production environments.
Announcement of innovative approaches to the design and manufacturing of standard and custom biologics, including peptides, proteins, and antibodies.